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Althoughmost oncogenic phenotypes of PTEN loss are attributed to AKT activation, AKT alone is not
sufficient to induce all of the biological activities associated with PTEN inactivation. We searched for
additional PTEN-regulated pathways through gene set enrichment analysis (GSEA) and identified
genes associatedwith JNK activation.PTEN null cells exhibit higher JNK activity, and genetic studies
demonstrate that JNK functions parallel to and independently of AKT. Furthermore, PTEN deficiency
sensitizes cells to JNK inhibition and negative feedback regulation of PI3K was impaired in PTEN null
cells. Akt and JNK activation are highly correlated in human prostate cancer. These findings implicate
JNK in PI3K-driven cancers and demonstrate the utility of GSEA to identify functional pathways using
genetically defined systems.INTRODUCTION
Inactivation of the tumor suppressor PTEN is among the
most common genetic lesions in human cancer. PTEN
functions as a tumor suppressor by dephosphorylating
the lipid products of PI3K, thus limiting the intracellular
pool of these second messengers and attenuating down-
stream signaling. Loss of PTEN causes an increase inintracellular PIP3 levels and activation of PH-domain-
containing molecules such as AKT. AKT phosphorylates
substrates involved in mediating survival from apoptosis,
proliferation, angiogenesis, and the regulation of glucose
metabolism (Vivanco and Sawyers, 2002).
The serine/threonine kinase mTOR is an effector of AKT.
AKT derepresses mTOR activity by phosphorylating TSC2
(Inoki et al., 2002), a negative regulator of mTOR function.SIGNIFICANCE
PTEN is the secondmost commonly mutated tumor suppressor in human cancers. We searched for pathways de-
regulated by PTEN inactivation using isogenic pairs of PTEN wild-type and PTEN knockdown cell lines and gene
set enrichment analysis. The JNK pathway was significantly associated with PTEN loss and chosen for validation.
We confirmed biochemical activation of JNK in PTEN-deficient cells and found that PTEN inactivation increases
sensitivity to JNK inhibition in a synthetic lethal-like fashion. Concurrent activation of AKT and JNK synergized
in transformation assays. Interestingly, PTEN null cells have a defect in IRS-1-regulated feedback inhibition of
PI3K that permits chronic activation of the pathway. These results implicate JNK as a critical component of the
PTEN/PI3K pathway and a potential therapeutic target.Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc. 555
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PTEN Regulates JNK Activity and FunctionTumors with PTENmutations are sensitized to the growth-
suppressive action of mTOR inhibitors, indicating that
PTEN null cancers become dependent on mTOR-driven
signals (Neshat et al., 2001; Podsypanina et al., 2001;
Wendel et al., 2004; Yilmaz et al., 2006). Understanding
the molecular pathways downstream of PTEN may iden-
tify additional targets for the treatment of tumors with
dysregulated PI3K function.
Although AKT explains many of the phenotypes associ-
ated with PTEN inactivation, the biological consequences
of PTEN gene targeting and genetic activation of AKT are
not completely overlapping. Mice with prostate-specific
PTEN inactivation develop invasive carcinoma with com-
plete penetrance (Trotman et al., 2003; Wang et al.,
2003). In contrast, transgenic mice carrying an activated
allele of AKT under the regulation of a prostate-specific
promoter develop prostate intraepithelial neoplasia (PIN)
but did not progress to cancer (Majumder et al., 2003).
These data as well as findings from other models raise
the possibility that additional pathways downstream
from PI3K can complement AKT in tumorigenesis caused
by PTEN loss. For example, in an in vitro model of breast
cancer that relies on concurrent expression of hTERT,
SV40 large T antigen, and activated PI3K for transforma-
tion, activated alleles of AKT and RAC1 can replace
PI3K (Zhao et al., 2003), suggesting that these two signals
may contain most (if not all) of the oncogenic signals trans-
duced by PI3K.
Several groups have reported transcriptional signatures
of PTEN, typically through reconstitution experiments in
PTEN-deficient tumor cells (Hong et al., 2000; Li et al.,
2006; Musatov et al., 2004; Simpson et al., 2001; Stolarov
et al., 2001). While useful, this approach does not reflect
the physiologic situation in tumors where PTEN expres-
sion is lost rather than restored. Here, we conducted
such experiments using isogenic tumor cell line pairs in
which PTEN inactivation was engineered through RNA in-
terference. We also used the analytical method known as
gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) to search for pathways dysregulated as a conse-
quence of PTEN loss, as this approach can offer advan-
tages over traditional analytical methods in identifying
coordinately regulated gene sets versus differences in
expression of single genes (Majumder et al., 2004; Monti
et al., 2005; Mootha et al., 2003).
Among the gene sets that were consistently enriched in
PTEN-deficient samples was the Jun N-terminal Kinase
(JNK) pathway, which attracted our attention due to
opportunities for pharmacological intervention. We con-
firmed functional upregulation of the pathway in Pten
knockout (KO) mouse embryonic fibroblasts (MEF). We
also found the increase in Jnk activity was independent
of Akt activation. In addition, AKT and JNK synergized in
transformation assays, both in vitro and in vivo, further
suggesting that AKT and JNK function in parallel rather
than in a linear pathway. Conversely, both Jnk inhibition
(specifically JNK1) and JunD inactivation selectively in-
hibited the growth of Pten null cells. Finally, we found
PTEN null cells maintain constitutive activation of the
556 Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc.PI3K pathway, in part, through loss of an IRS1-mediated
feedback loop. Our findings implicate JNK and AKT as
complementary signals in PIP3-driven tumorigenesis
and suggest that JNK may be a therapeutic target in
PTEN null tumors.
RESULTS
PTEN Loss Enhances Expression of Genes
in the JNK Pathway
Although much is known about the contribution of AKT
to PI3K-driven tumorigenesis, the identity and biological
relevance of AKT-independent pathways downstream of
PI3K are relatively unexplored. To identify additional path-
ways that may participate in tumorigenesis caused by
PTEN loss, we took an unbiased approach to look for
gene sets that were enriched in PTEN-deficient cells. We
first generated a series of human isogenic cell line pairs
in which PTEN was knocked down by RNA interference.
We derived stable lines of A431 (epidermoid carcinoma),
HCC827 (non-small-cell lung carcinoma), and SKBR-3
(mammary adenocarcinoma) cells retrovirally transduced
with a small hairpin RNA (shRNA) targeting PTEN. These
lines were chosen to sample PTEN inactivation in several
tissue types reflective of the human cancers with PTEN
loss. PTEN expression was reduced by approximately
90% at the protein level (Figure 1A).
We used GSEA to identify gene sets enriched in each of
the three PTEN-deficient sublines (hereafter referred to as
PR for PTEN RNAi) compared to their parental counter-
parts. Thirty-six gene sets were enriched in each of the
three individual cell line pairs (Figure 1B, Venn diagram)
and presumably reflect ‘‘consensus’’ pathways deregu-
lated by PTEN loss irrespective of tissue specificity and
genetic background. Thirty-four of these 36 commonly
enriched gene sets were also identified through a related
analysis strategy where all three PTEN-positive cell lines
were pooled into a single class and compared to the
pooled PR sublines (Figure 1C). Among these 34 gene
sets, the JNK pathway (see Figure S1A for enrichment
data in the Supplemental Data available with this article
online) was of particular interest because JNK is essential
for oncogene-driven transformation in certain contexts
(Hess et al., 2002; Rodrigues et al., 1997) and is amenable
to targeting by small molecule kinase inhibitors (Manning
and Davis, 2003). Upon closer inspection of the mRNAs
included into the JNK pathway gene set, we noted that
three JNK phosphatases (DUSP4, DUSP8, and DUSP10)
were included with 20 JNK pathway kinases, adaptors,
and downstream transcription factor targets such as
JUN andATF2 (Table S1). Since the kinases and phospha-
tases presumably function in an opposing fashion, we
removed the three JNK phosphatases from the original
JNK pathway gene set and repeated the GSEA. The
curated JNK gene set (excluding phosphatases) was
again enriched in the pooled PTEN null cells and with
even greater statistical significance than the original
gene set (higher normalized enrichment score and lower
p value) (Figure 1C, bottom). The JNK phosphatase gene
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PTEN Regulates JNK Activity and FunctionFigure 1. PTEN Inactivation Leads to Enrichment of a Small Number of Gene Sets
(A) RNAi-mediated inactivation of PTEN was confirmed by western blot in the indicated cell lines (the suffix -PR indicates PTEN RNAi). Immunoblot
analysis using a p85 antibody was also carried out as a loading control.
(B) Venn diagram of three different GSEA analyses run on the three parental and -PR tumor line pairs. The number of gene sets associated with PTEN
loss and the overlap between cell line pairs is shown.
(C) List of the top 36 genes sets enriched in all three cell line pairs. The JNK pathway gene set is highlighted in yellow. The table at the bottom shows
the repeat GSEA when the three JNK phosphatases were removed from the curated JNK pathway gene set (see also Table S1). (NES, normalized
enrichment score).Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc. 557
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PTEN Regulates JNK Activity and FunctionFigure 2. The JNK Pathway Is Activated
as a Result of PTEN Loss
(A) Exponentially growing A431 and A431-PR
cells were treated with 100 ng/ml anisomycin.
At the indicated times, cells were lysed and
the lysates were normalized and subjected to
immunoblot using the indicated antibodies.
(B) A431 and A431-PR cells were serum
starved for 48 hr and subsequently challenged
with 10 ng/ml EGF. At the indicated times, cells
were lysed and the lysates were normalized
and subjected to immunoblot using the indi-
cated antibodies.
(C) Exponentially growing Pten+/+ and Pten/
MEFs were treated with 100 ng/ml anisomycin.
At the indicated times, cells were lysed and the
lysates were normalized and subjected to
immunoblot using the indicated antibodies.
(D) Pten+/+ and Pten/ MEFs were serum
starved for 24 hr and subsequently challenged
with 150 ng/ml EGF. At the indicated times,
cells were lysed and the lysates were normal-
ized and subjected to immunoblot using the
indicated antibodies.set was negatively enriched (bottom table in Figure 1C and
Figure S1B), providing further confidence in the PTEN
loss/JNK pathway association.
PTEN Loss Leads to Enhanced JNK Activation
To biochemically evaluate the GSEA-predicted conse-
quences of PTEN loss on JNK function, we measured
growth factor- and chemical stress-induced JNK activa-
tion in A431 and A431-PR cells using activation-state-
specific antibodies against JNK. While both cell lines
showed identical JNK activation profiles in response to
anisomycin (Figure 2A), EGF-induced JNK activation was
higher and persisted longer in PTEN-deficient cells
(Figure 2B). We observed a similar pattern of Jnk activation
in MEFs carrying a ‘‘floxed’’ Pten allele (Freeman et al.,
2003) deleted by retroviral delivery of Cre recombinase
(Figures 2C and 2D) and when fetal bovine serum (FBS)
558 Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc.rather than EGF was used as the activation stimulus in
both MEFs and A431 cells (Figure S2 and data not shown).
In addition to growth factor-induced Jnk activity,
steady-state Jnk activity was higher in Pten null MEFs,
albeit at more modest levels. Phospho-Jnk levels were
consistently elevated in Pten/ MEFs (Figure S3A), and
this increase was confirmed by in-gel kinase assays
(Figure S3B). Of note, the magnitude of Jnk1 activation
(approximately 2-fold higher in Pten-deficient cells) was
greater than Jnk2 (approximately 50% increase). Phos-
phorylation levels of the Jnk substrate c-Jun were also
higher in Pten/ MEFs (Figure S3A). JunD phosphoryla-
tion, recognized by the same phospho-c-Jun antibody
as a faster migrating band, was increased as well (best
seen in Figures 2D, 5B, and 6C). Levels of both phos-
pho-c-Jun and phosphoS6 (a downstream readout of
Akt) were also higher in Pten/ brain lysates, derived
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PTEN Regulates JNK Activity and Functionfrom a floxedPten/Nestin-Cremouse cross (Groszer et al.,
2006) (Figure S3C). In a reciprocal set of experiments, ec-
dyson-induced PTEN expression in the PTEN null glioma
cell line U87 (Stolarov et al., 2001) repressed JNK and
AKT activity (Figure S3D).
The Increase in JNK Activity Elicited by PTEN Loss
Occurs Through Multiple Mechanisms
Previous reports have shown that a constitutively active
PI3K allele is sufficient to activate JNK (Klippel et al.,
1996); therefore, we suspected that Jnk activation in
Pten null cells would also be Pi3k-dependent. The Pi3k
inhibitor LY294002 inhibited Jnk activation in Pten null
MEFs and in a prostate cancer cell line derived from
Pten knockout mice (PTEN-CaP8) in a dose-dependent
fashion, but to a much lesser degree in wild-type MEFs
or in a Pten wild-type prostate cancer cell line derived
from large T antigen transgenic mice (TRAMP-C1) (Foster
et al., 1997)(Figures 3A and 3B). Similar findings were ob-
served using a Jun reporter assay, where the increased
Jnk activity seen in Pten/ MEFs was restored to the
baseline levels seen in Pten+/+ MEFs by LY294002 treat-
ment (Figure 3C, red bar). Conversely, Jnk reporter activity
was increased in Pten wild-type MEFs expressing a con-
stitutively active allele of Pi3k (Myr-p110*) but not in Pten
null MEFS, consistent with the notion that Pi3k activation
and Pten inactivation are likely epistatic (Figure 3D).
We next considered the molecular basis of Jnk activa-
tion through the Pi3k/Pten pathway. Previously, we
reported that Pten null MEFs have elevated Cdc42 and
Rac1 catalytic activity (Liliental et al., 2000). Mixed-lineage
kinase-3 (Mlk3) is a Jnk kinase kinase downstream of
Rac1, and the Drosophila Mlk3 homolog Slipper was one
of several genes isolated in a suppressor screen of the
Pten knockdown phenotype in flies (Kiger et al., 2003).
Therefore, we asked if the elevated Jnk activity in Pten
null cells is dependent on Mlk3 and Rac1. In the c-jun
reporter assay, dominant negative MLK3 selectively
repressed Jnk activity in Pten/ MEFs (Figure 3C, light
green bar). Jnk activity was also suppressed by a dominant
negative allele of RAC1 but with less specificity forPtennull
MEFs than seen with Mlk3 (Figure 3C, yellow bar).
Based on our GSEA analysis, we suspected that PTEN
might also regulate JNK through its effects on transcrip-
tion. To address this possibility, we repeated the EGF
induction experiments described above in the presence
of the transcriptional inhibitor actinomycin-D (ActD).
Peak JNK activation (reached after 15 min of EGF stimula-
tion) was unaffected by ActD; however, the extended
longevity of the signal seen at 120 min in PTEN-deficient
cells was reversed (Figure 3E). In fact, JNK phosphoryla-
tion dropped below basal levels at this time point
(Figure 3E, compare the 0 and 120 min time points in
A431-PR cells). Taken together, these data implicate at
least two mechanisms by which PTEN loss affects JNK
activity. Increased PIP3 levels are most likely responsible
for the higher peak level of growth factor-induced JNK
activation in PTEN null cells, whereas the increased dura-
tion of JNK activation is transcription-dependent.PTEN Loss Sensitizes Cells to JNK
Pathway Inhibition
To investigate the biological importance of Jnk deregula-
tion by Pten loss, we studied the effects of Jnk pathway
inhibition on cell growth. Using the isogenic MEF model,
we acutely infected cells with retroviral shRNAs targeting
either Jnk1 or Jnk2 (Figure 4A, right panel) or the Jnk tran-
scription factor target JunD (Figure 4B, right panel). JunD
was chosen because (1) it transduces Jnk survival signals
(Lamb et al., 2003), (2) it promotes (rather than sup-
presses) growth when the tumor suppressor MEN1 is
inactivated (Agarwal et al., 2003) (and might function
similarly with Pten) and (3) pJunD levels are increased in
Pten null MEFs. Both Jnk1 and JunD knockdown selec-
tively inhibited the growth of Pten null MEFs by about 50
percent (Figures 4A and 4B, left panels). JunD knockdown
in wild-type MEFs caused a modest increase in prolifera-
tion, consistent with the tumor suppressor function of
JunD in certain contexts (Pfarr et al., 1994). Jnk1 RNAi
was similarly effective in selectively blocking the growth
of Pten null (PTEN-CaP8), but not Pten-positive
(TRAMP-C1), prostate cancer cells (Figure 4C). In contrast
to Jnk1, the antiproliferative effects of Jnk2 knockdown
were seen regardless of Pten background (Figure 4A,
left panel, yellow bars), in agreement with previous work
showing that JNK2 but not JNK1 antisense oligonucleo-
tides have broad antiproliferative activity (Du et al., 2004).
We also examined the effects of a relatively selective
pyridinylamide JNK inhibitor (hereafter referred to as
JNKi) (Szczepankiewicz et al., 2006) in the isogenic Pten
MEFs. Similar to the Jnk1 and JunD knockdown studies,
JNKi blocked the growth of Pten null MEFs without affect-
ing wild-type MEFs (Figure 4D, left panel) at concentra-
tions that reduced c-Jun phosphorylation to comparable
levels in both lines (Figure 4D, right panels). Total c-Jun
levels were lower in JNKi-treated cells as expected since
c-Jun expression is positively regulated by its own activity
(Angel et al., 1988) (Figure 4D, right panel and Figure S4A).
We observed similar results with the widely used but
less specific anthrapyrazolone JNK inhibitor SP600125
(Figures S4B and S4C). The collective data from these
and the RNA interference experiments indicate that
Pten null cells acquire dependence on sustained Jnk
activation.
In addition to its role in mediating proapoptotic signals
(Davis, 2000), Jnk is required for malignant transformation
in certain contexts, such as by the BCR-ABL leukemia
oncogene (Dickens et al., 1997; Hess et al., 2002; Raitano
et al., 1995; Rodrigues et al., 1997). To determine if the
antiproliferative effects of Jnk1 inhibition observed in vitro
extended to tumor models, we assessed the impact of
Jnk1 knockdown on tumorigenicity. Retroviral delivery of
Jnk1 shRNA into Pten null MEFs almost completely in-
hibited subcutaneous tumor formation in SCID mice
(Figure 4E). Similarly, Jnk1 knockdown (Figure 4F) re-
duced tumorigenicity of PTEN-CaP8 by 50 percent
(Figure 4G). Conversely, Jnk1 shRNA did not substantially
affect tumor incidence in TRAMP-C1 cells, albeit with
less-efficient Jnk1 knockdown than in PTEN-CaP8 cells
Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc. 559
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PTEN Regulates JNK Activity and FunctionFigure 3. PTEN Regulates JNK Function by Multiple Mechanisms
(A and B) Pten+/+ and Pten/ MEF, or PTEN-CaP8 and TRAMP-C1 cells were treated with the indicated doses of LY294002 for 6 hr and then lysed.
Lysates were subjected to immunoblot using activation state-specific antibodies against phospho-Jnk (pJnk), phospho-c-Jun (pJun), and pAkt
(pAKT), or antibodies against total Jnk, c-Jun, Akt, actin, and Pten.
(C) Pten+/+ and Pten/ MEFs were cotransfected with either empty vector, dominant-negative RAC1 (DN Rac) or dominant-negative MLK3 (DN
MLK3) constructs along with AP-1 PathDetect plasmids, or were transfected with PathDetect plasmids and treated with 10 mM LY294002. Jnk activity
(mean ± SEM, n = 3) was measured by luciferase reporter assay 36 hr after transfection.
(D) Pten+/+ and Pten/ MEFs were co-transfected with either empty vector or constitutively active PI3K (M-p110*) along with AP-1 PathDetect
plasmids. Jnk activity (mean ± SEM, n = 3) was measured as in (C) 36 hr after transfection.
(E) A431 and A431-PR cells were serum starved for 48 hr and pretreated with 10 ng/ml actinomycin D for 15 min. Cells were then kept in Actinomycin D
where indicated and stimulated with 10 ng/ml EGF for the indicated times. Cells were lysed and lysates were normalized before subjecting them to
immunoblot with the indicated antibodies. pJNK levels were quantified by densitometry and expressed as a ratio of pJNK over total JNK.560 Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc.
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tumorigenicity assays relative to in vitro proliferation rates
suggests that Jnk1 may be even more critical for onco-
genic growth.
Jnk and Akt Are Activated Independently
and Synergize in Transformation Assays
To determine if Jnk and Akt are activated independently
by Pi3k or sequentially through a linear signaling pathway,
we measured the effect of loss of function of one on the
biochemical activity of the other. Dual inactivation of
Jnk1 and Jnk2 by gene targeting had no effect on in-
sulin-induced Akt activation in MEFs (Figure 5A), providing
evidence that Akt is not downstream of Jnk. We
conducted the reciprocal experiment, asking whether
Jnk was downstream of Akt, by inhibition of Akt using
a previously characterized compound that selectively
interferes with PH domain/PIP3 binding (Barnett et al.,
2005; Zhao et al., 2005). Jun phosphorylation was unaf-
fected by doses that clearly lowered Akt and S6 phos-
phorylation (Figure 5B). These results suggest that Akt
and Jnk are independently activated by Pi3k through
parallel pathways rather than in sequence. One prediction
is that constitutive activation of both Jnk and Akt should
give a greater biological effect than individual activation
of each signal. To test this hypothesis, we expressed
activated AKT and activated JNK separately or simulta-
neously in NIH3T3 cells by retroviral infection and com-
pared growth rates in soft agar and in mice. Constitutive
JNK activation was achieved using a modified version of
a previously characterized MKK7/JNK1 fusion protein
(Lei et al., 2002) (hereafter called JNK*), where phospho-
mimetic mutations (Wolter et al., 2002) were introduced
in the MKK7 moiety to achieve maximal activation.
Neither AKT nor JNK was sufficient to induce anchorage-
independent growth, whereas the combination clearly
was (Figure 5C, left panel). Furthermore, the growth of
these doubly transduced colonies, upon replating in soft
agar after brief propagation in vitro, was completely in-
hibited by SP600125 treatment (Figure 5C, right panel).
Similarly, doubly transduced NIH3T3 cells formed larger
tumors more quickly after subcutaneous implantation in
SCID mice (Figure 5D) and grew more quickly in liquid
culture (Figure S5).
Because PTEN loss is common in glioma (Wang et al.,
1997) and JNK activity is elevated in some of these tumors
(Antonyak et al., 2002), we extended our findings to an
immortalized human astrocyte model of human glioma
(NHA) (Sonoda et al., 2001). As with NIH3T3 cells, only
astrocytes expressing both transgenes formed colonies
in soft agar (Figure 5E), and doubly transduced astrocytes
generated tumors in animals more quickly and with higher
penetrance than astrocytes expressing AKT alone
(Figure 5F). JNK*-expressing and vector control astro-
cytes did not form tumors. Collectively, these biochemical
and biological studies support a model whereby JNK
functions in parallel with AKT to promote tumorigenesis
and are consistent with an earlier report that RAC1 (pre-
sumably acting upstream of JNK) and AKT could replacePI3K in a breast cancer transformation model (Zhao
et al., 2003).
Pten Null Cells Have an Impaired Negative Feedback
Loop, Leading to Prolonged Pi3k Activation
Although PI3K pathway signaling is primarily regulated by
PTEN, there has been much recent interest in two negative
feedback loops, involving S6 kinase and JNK, respec-
tively, that attenuate insulin-induced PI3K activation by
phosphorylating insulin receptor substrate (IRS) proteins
at serine residues leading to their inactivation (Fujishiro
et al., 2003; Gual et al., 2005; Lee et al., 2003). JNK1
appears to be the most relevant JNK isoform in mediat-
ing feedback because JNK1-deficient (but not JNK2-
deficient) mice are protected from diet-induced insulin
resistance (Hirosumi et al., 2002). One prediction of our
dual AKT/JNK pathway activation model is that both
negative feedback loops would be active; therefore, cells
should be unable to sustain PI3K activity. Yet, PTEN-
deficient tumors have constitutively increased PI3K
signaling, suggesting they may be resistant to negative
feedback (Figure 6A).
To address this apparent paradox, we first used the
mTOR inhibitor rapamycin, which blocks S6 kinase-
mediated negative feedback (Easton et al., 2006; O’Reilly
et al., 2006; Shi et al., 2005). Wild-type MEFs treated with
rapamycin showed a dose-dependent increase in the
steady state levels of phospho-Akt (as expected [O’Reilly
et al., 2006; Sun et al., 2005]), but Pten null MEFs did not,
suggesting that negative feedback is impaired in Pten-
deficient cells. We observed similar results using the
JNK inhibitor: JNKi treatment led to an increase in
steady-state pAkt levels in wild-type MEFs but not in
Pten null MEFs. Therefore, both mTor and Jnk regulate
pathway(s) responsible for negative feedback of Akt that
is impaired in Pten null cells. Similar to pAkt, the steady-
state level of Jnk phosphorylation was increased in
JNKi-treated cells, indicative of additional negative feed-
back, but this effect was observed regardless of Pten
status and therefore suggests a Pi3k-independent nega-
tive feedback loop (Figure 6C and Figure S4A).
Since Irs proteins are one target of mTor- and Jnk-
dependent negative feedback, we investigated their
expression level and phosphorylation status. mRNA
(Figure S6) and protein (Figure 6D, left panel) levels of
both Irs1 and Irs2 were substantially lower in Pten null
MEFs. IRS-1 levels were similarly reduced (in cells with
detectable basal levels) in the PTEN knockdown tumor
sublines used for the GSEA analysis described earlier
(Figure 6D, right panel). These findings are consistent
with a reciprocal experiment performed by others in which
PTEN reconstitution led to an increase in IRS-2 levels
(Simpson et al., 2001).
Next, we assessed the impact of Pten loss on insulin-
induced Irs-1 phosphorylation and subsequent complex
formation with the insulin receptor (Ir-b). LY294002 was
used in some experiments as a tool to block down-
stream signal propagation and thereby eliminate negative
feedback. As expected (Haruta et al., 2000), tyrosine
Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc. 561
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PTEN Regulates JNK Activity and FunctionFigure 4. Pten Loss Sensitizes Cells to Jnk Inhibition
(A) Pten+/+ and Pten/ MEF were retrovirally infected with Jnk1-targeted shRNA (J1R) or Jnk2-targeted shRNA (J2R). Seventy-two hours after
infection, lysates were made and analyzed by immunoblot with the indicated antibodies (bottom). Cells were also seeded and counted the day after
seeding and 5 days later. Growth is expressed as the percentage increase in cell number between day 1 and day 5 in relation to vector-infected cells
(100% growth) (left, mean ± SEM, n = 3).562 Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc.
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lated cells (Figure 6E). Despite the low amounts of Irs-1
protein present in Pten null MEFs, the relative level of tyro-
sine-phosphorylated Irs-1 was substantial compared to
that seen in wild-type MEFs (Figure 6E, compare lanes 2
and 3 with lanes 6 and 7). This enhanced efficiency of
Irs-1 tyrosine phosphorylation in Pten null cells was no
longer apparent after LY294002 treatment, as tyrosine-
phosphorylated Irs-1 levels were restored to baseline
(Figure 6E, lanes 7 and 8). The kinetics of Irs-1/Ir-b com-
plex assembly was also altered in Pten null cells. In both
wild-type and Pten null MEFs, Ir-b was detected in Irs-1
immunoprecipitates within 5 minutes of insulin stimulation
(Figure 6F). After 3 hr, this complex was no longer detect-
able in wild-type cells but persisted in Pten null MEFs
(Figure 6F, compare lanes 4 and 9).
Since tyrosine phosphorylation of Irs-1 is thought to
preclude serine phosphorylation (Pederson et al., 2001)
(and subsequent degradation/inactivation), we propose
that the pool of unphosphorylated Irs available for nega-
tive feedback regulation is limited in Pten null cells.
JUN and AKT Phosphorylation in Human Prostate
Cancer Is Positively Correlated
Next we evaluated the relevance of PI3K-driven JNK path-
way activation in human cancer by immunohistochemical
staining of prostate cancer tissue microarrays (TMAs) for
phospho-JUN (pJUN), phosphor-AKT (pAKT), phosphoS6
(pS6), and PTEN. (Figure 7A). pJUN staining was positively
correlated with nuclear pAKT (Spearman’s Rho = 0.38, p <
0.0001) and cytoplasmic pAKT (Spearman’s Rho = 0.26,
p = 0.008) (Figure 7B). pJUN and pS6 were also correlated
(Spearman’s Rho = 0.57, p < 0.0001). There was a trend
showing a negative correlation between PTEN expression
and pJUN whose strength was comparable to the associ-
ation between PTEN loss and pAKT or pS6 staining, but
neither reached statistical significance. Dual pJUN/PTEN
staining with quantum dot-labeled antibodies showed
that pJUN and PTEN expression are mutually exclusive
in the epithelial cells of prostate tumor sections
(Figure 7C). Since AKT phosphorylation is a known marker
of PTEN loss, the fact that the associations between PTEN
loss and pAKT or pJUN failed to reach statistical signifi-cance may be indicative of alternative mechanisms of
PI3K pathway activation in prostate cancer. The signifi-
cant positive correlation between pJUN and pAKT
suggests that these two molecules are activated by a
common upstream signal.
DISCUSSION
Much effort is focused on identifying gene expression net-
works with the hope that such tools will assist in mining the
vast information generated through global expression
profiling studies. Gene set enrichment analysis (GSEA)
allows detection of modest but coordinated changes in
expression of genes involved in a common biological
function, rather than concentrating on specific gene
changes, and has been successful in elucidating mecha-
nisms of insulin resistance and diabetes (Houstis et al.,
2006; Mootha et al., 2003; Petersen et al., 2004; Subrama-
nian et al., 2005). Here we used GSEA to identify pathways
associated with PTEN loss using expression data derived
from a small number of well-defined isogenic tumor lines
(Figure 1A and Figure S7). One lead from this analysis,
JNK pathway activation, was then validated in a series
of biochemical and biological studies using genetically
defined systems. Finally, we demonstrate that the asso-
ciation originally generated from tumor line data sets
(through GSEA) is relevant in human clinical samples. Of
note, we have conducted further GSEA runs using expres-
sion data sets from human prostate cancer samples
(http://www.broad.mit.edu/cgi-bin/cancer/publications/
pub_paper.cgi?mode=view&paper_id=75) annotated for
PTEN status by immunohistochemical staining. The JNK
pathway gene set also emerged from this analysis, but
the strength of the association with PTEN loss was weaker
than that found using the isogenic tumor lines (J.R., N.P.,
and I.V., unpublished data). This presumably reflects the
heterogeneity present within human tumor samples and
argues for the potential value in starting with genetically
defined (albeit artificial systems) for generating initial
hypotheses from global data sets then moving to clinical
material for validation.
The PTEN/JNK pathway association identified by
GSEA was confirmed through a series of biochemical(B) Pten+/+ and Pten/ MEF were retrovirally infected with JunD-targeted shRNA (JDR). Seventy-two hours after infection, lysates were made and
analyzed by immunoblot with the indicated antibodies (bottom). Cells were also seeded and counted as in (A). Growth is expressed as the percentage
increase in cell number from day 1 to day 5 in relation to vector-infected cells (100% growth) (left, mean ± SEM, n = 3).
(C) TRAMP-C1 and PTEN-CaP8 cells were retrovirally infected with Jnk1-targeted shRNA (J1R). Seventy-two hours after infection, lysates were made
and analyzed by immunoblot with the indicated antibodies (bottom). Cells were also seeded and counted as in (A). Growth is expressed as the
percentage increase in cell number from day 1 to day 5 in relation to vector-infected cells (100% growth) (left, mean ± SEM, n = 3).
(D) Pten+/+ and Pten/ MEFs were seeded at equal densities. Fifteen hours after seeding, cells were counted (day 1) and treated with either DMSO
(vehicle) or 4 mM JNKi. Cells were counted again 5 days later. Growth is expressed as the percentage increase in cell number from day 1 to day 5 in
relation to DMSO-treated cells (100% growth) (left, mean ± SEM, n=3). Cells were also separately treated for 8 hr, as indicated, for biochemical
analysis. Lysates were made and examined by immunoblot using the indicated antibodies (middle). c-Jun phosphorylation was quantified by
densitometry (right).
(E) Pten/ MEF (control) and Pten/ MEF infected with a Jnk1-targeted shRNA (from 3A) were injected subcutaneously into the flanks of SCID mice.
Tumor growth was followed and measurements (mean ± SEM) taken at the indicated times.
(F) TRAMP-C1 and PTEN-CaP8 cells were infected with a Jnk1-targeted shRNA (J1R). Seventy-two hours after infection, cell lysates were subjected
to immunoblot analysis with the indicated antibodies.
(G and H) The remaining cells (from B) were injected subcutaneously into SCID mice (n = 6) and tumor incidence was followed over the indicated time
periods.Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc. 563
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PTEN Regulates JNK Activity and FunctionFigure 5. AKT and JNK Are Activated Independently of Each Other and Synergize in Transformation Assays
(A) Wild-type (WT) and Jnk1/2 double KO (Jnk null) MEFs were serum starved and challenged with 100 nM insulin for the indicated times. Lysates were
made and subjected to immunoblot using the indicated antibodies.
(B) Wild-type (Pten+/+) and Pten null (Pten/) MEFs were treated with the indicated doses of AKT inhibitor (AKT inhibitor VIII, Calbiochem) for 8 hr.
After treatment, cells were lysed and subjected to immunoblot using the indicated antibodies.
(C) NIH3T3 cells were retrovirally transduced with a control virus or viruses carrying constitutively active alleles of epitope-tagged (HA) AKT (AKT*),
(FLAG) JNK (JNK*), or both. Seventy-two hours after infection, cells were lysed and analyzed by western blot using HA (AKT*), FLAG (JNK*), or Actin
antibodies (left inset). The remaining cells were plated in soft agar. Colonies were counted three weeks after plating (left bar graph, mean ± SEM,
n = 3). A random doubly-transduced clone (AKT*JNK*) from (C) was picked, expanded, and replated in soft agar in the presence or absence of
5 mM SP600125 (right bar graph). Colonies were counted 3 weeks after plating (mean ± SEM, n = 3).
(D) Cells from (C) were injected subcutaneously into SCID mice and tumor volume (mean ± SEM) was measured at the indicated times.
(E) Normal human astrocytes (NHA) were stably transduced with the indicated viruses. Transgene expression was confirmed by western blot analysis
using HA (AKT*), FLAG (JNK*), or Actin antibodies (inset). Cells expressing the various transgenes were plated in soft agar. Colonies were counted
3 weeks after plating (mean ± SEM, n = 3).
(F) Astrocytes expressing the indicated transgenes were injected subcutaneously into SCID mice and tumor incidence assessed at the indicated
times.and biological studies using mouse and human cell line
models. The evidence includes (1) increased JNK,
JUND, and c-JUN phosphorylation (modestly at steady
state and significantly after growth factor induction, but
564 Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc.not after stress induction) and increased c-Jun transcrip-
tional activity in PTEN null cells and tissues, (2) a synthetic
lethal-like dependence of PTEN null cells on JNK1 and
JUND for in vitro proliferation and tumor growth, (3)
Cancer Cell
PTEN Regulates JNK Activity and FunctionFigure 6. Pi3k Negative Feedback Regulation Is Impaired in Pten Null Cells
(A) A model of PI3K negative feedback regulation. Activated insulin receptor phosphorylates IRS-1 at tyrosine residues inducing downstream
activation of PI3K. PI3K activates S6K and JNK, both of which phosphorylate IRS-1 at serine residues inducing its degradation and terminating
the signal.
(B) Pten+/+ and Pten/ MEFs were treated with the indicated doses of rapamycin for 8 hr. After treatment, cells were lysed and lysates analyzed by
western blot with the indicated antibodies.
(C) Pten+/+ and Pten/ MEFs were treated for 8 hr with the indicated doses of JNKi. Normalized whole-cell lysates were subjected to western blot
analysis with the indicated antibodies.
(D) Irs-1 and Irs-2 protein levels were measured in lysates from Pten+/+ and Pten/ MEFs by immunoblot. Levels of p85 Pi3k were also measured by
western blot for comparison (left). Irs-1 and p85 protein levels were also measured in lysates from the isogenic cell line pairs used for the GSEA as
indicated (right).
(E) Pten+/+ and Pten/ MEFs were serum-starved for 24 hr, then challenged with 100 nM insulin for 1 min or 3 hr and treated with 30 mM LY294002 as
indicated. After treatment, lysates were made and analyzed by western blot with the indicated antibodies.
(F)Pten+/+ andPten/MEF cells were serum-starved for 24 hr, then challenged with 100 nM insulin for the indicated times in the presence or absence
of 30 mM LY294002. Normalized whole-cell lysates (WCL) were analyzed by western blot using the indicated antibodies or subjected to immunopre-
cipitation using Irs-1 antibodies. Irs-1 immunoprecipitates were analyzed by western blot using the indicated antibodies.oncogene cooperativity of JNK with AKT, and (4) associa-
tion of pJUN and pAKT staining in human prostate cancer
specimens. We also show that growth factor-induced JNK
activation in Pten null cells is Pi3k-dependent via a known
pathway involving Rac1 and Mlk3, in agreement with
previous observations that Rac1 and Cdc42, two activa-
tors in the JNK pathway, exhibited increased catalytic ac-
tivity in Pten null MEFs (Liliental et al., 2000). JNK activa-tion in PTEN null cells is further enhanced by a defect in
the termination of JNK signaling, which appears to be me-
diated through altered transcriptional regulation of down-
stream target mRNAs. The JNK phosphatases (DUSP10,
4, and 8) that are downregulated in PTEN null cells are rea-
sonable candidates.
Our studies also shed new light on the mechanism of
negative feedback regulation of PI3K, an area of growing
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PTEN Regulates JNK Activity and FunctionFigure 7. Phospho-JUN and Phospho-AKT Immunohistochemical Staining Are Positively Correlated in Human Clinical Prostate
Cancer Samples
(A) Representative images from prostate cancer tissue microarrays stained with PTEN, pJUN, pAKT, and pS6 antibodies.
(B) Relationship between pJUN, pAKT, pS6, and PTEN staining scores from tumor tissue microarray samples using the Spearman correlation
coefficient.
(C) Dual PTEN (yellow) and pJUN (red) quantum-dot-labeled antibody staining of normal prostate and prostate cancer samples. The yellow arrow
points to PTEN positive cells. The green arrow points to pJUN-positive cells.interest due to the clinical use of mTOR inhibitors as
anticancer agents. These drugs can activate AKT in
some tumors due to loss of S6 kinase-mediated negative
feedback, potentially counteracting their intended anti-
cancer activity. IRS proteins, which function primarily
(upon tyrosine phosphorylation) to activate PI3K, are
also the targets of the S6 kinase and JNK negative feed-
566 Cancer Cell 11, 555–569, June 2007 ª2007 Elsevier Inc.back loop (through serine phosphorylation). Our data
demonstrate that IRS proteins in Pten null cells, which
are limited due to reduced mRNA levels, are more effi-
ciently phosphorylated on tyrosine and engaged in signal
transduction due to sustained complex formation with
Ir-b. We propose that this prolonged pattern of Irs tyrosine
phosphorylation and Ir-b complex formation limits the
Cancer Cell
PTEN Regulates JNK Activity and Functionpool available for serine phosphorylation by S6 kinase or
Jnk, thereby impairing negative feedback. The precise
mechanism by which PTEN loss alters IRS function needs
further exploration. One possibility is that sustained levels
of PIP3 caused by PTEN loss recruit IRS proteins to the
membrane through interaction with their PH domains
(Razzini et al., 2000; Voliovitch et al., 1995) and thereby
gain greater proximity to tyrosine phosphorylation by
receptor tyrosine kinases.
The cooperativity between AKT and JNK in transforma-
tion models is particularly relevant for therapeutics since
small molecule inhibitors of both targets are in clinical
development. JNK is known to promote apoptosis in
certain contexts, yet the proapoptotic effects of JNK are
suppressed by PI3K-driven signals (Lamb et al., 2003;
Lei et al., 2002; Xia et al., 1995). One might predict, then,
that AKT inhibition alone could unleash the proapoptotic
activity of JNK in PTEN null cells, whereas parallel inhibi-
tion of JNK and AKT may be counterproductive. However,
we found that proliferation, and particularly tumor forma-
tion, of PTEN null cells is suppressed by JNK1 inhibition,
analogous to the role of JNK1 in leukemic spread in a
murine BCR-ABL leukemia model (Hess et al., 2002).
This dual role of JNK1 is similar to that observed for
JUND (also implicated in our studies), which shifts from
tumor suppressor to oncogene in the context of MEN1
deletion (Agarwal et al., 2003). Therefore, dual inhibition
of AKT and JNK may be appropriate only in the context
of PTEN loss. Notably, somatic mutations in JNK1,
JNK2, and the upstream kinase MKK7 were recently
reported in human tumors, providing further evidence of
a role for this pathway in transformation (Greenman
et al., 2007). As inhibitors of AKT, JNK, PI3K, mTOR,
and the insulin and IGF receptor tyrosine kinases all
make their way into the clinic, our findings reinforce the
need to document tumor genotype to make an informed
assessment of clinical response.
EXPERIMENTAL PROCEDURES
GSEA Analysis
The human isogenic cell line pairs were profiled using Affymetrix
Human Genome U133 Plus 2.0 Arrays in duplicate. The data were
restricted to only those probes that were flagged as present in 1 out
of 4 samples. GSEA was performed using the publicly available desk-
top application from the Broad Institute (http://www.broad.mit.edu/
gsea/software/software_index.html). Genes represented by more
than one probe were collapsed using the XCollapseProbes utility to
the probe with the maximum value. The gene sets database used
was that of functional sets, s2.symbols.gmt. Due to the small number
of samples, p values were calculated by permuting the genes 1000
times. The classic enrichment statistic was selected. The HG-
U95Av2 clinical prostate cancer data set was restricted by rejecting
10% of the probes: those with the lowest signal intensity. This was
done by removing genes with signal lower than seven in 3 of 13 condi-
tions. The same procedure was repeated for GSEA.
Microarray Data Access
All microarray data from the isogenic cell line pairs used for GSEA have
been deposited in NCBIs Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO series
accession number GSE7562.Cell Culture and Agar Assays
MEFs and NIH-3T3 cells were grown in DMEM supplemented with 5%
fetal bovine serum (FBS). Normal human astrocytes (NHA) (gift from Dr.
Russell Pieper) were grown in DMEM supplemented with 10% FBS. To
generate Pten/ MEFs, Cre recombinase virus was made by trans-
fecting pMSCV-puro-Cre and ecotropic packaging plasmid into
293T cells. Virus was collected and Ptenlox/lox MEFs were infected.
Cells were selected with 3 ug/ml puromycin for 5 days. Jnk1 and
Jnk2 shRNA as well as constitutively active AKT (AKT*) and constitu-
tively active JNK (JNK*) ecotropic retroviruses were also made in this
manner, but the analysis was done 72 hr after infection. To generate
NHA cells expressing vector control, JNK*, AKT* or JNK*, and AKT*,
viruses were generated by transfecting pMSCV-Neo, JNK* or AKT*
into an amphotropic packaging cell line. Cells were infected and stable
expressors were selected by adding 500 ug/ml G418, or 3 ug/ml puro-
mycin into the media for 10 days. JNK*/AKT* double expressors were
generated by retrovirally introducing JNK* into NHA-AKT* cells and
selecting with G418 for 10 days. Soft agar assays were done as
previously described (Li et al., 1995).
In Vivo Tumor Growth
All animal experiments were approved by the UCLA Animal Research
committee and conducted according to relevant regulatory standards.
13 106 cells resuspended in 50% matrigel were injected into the flanks
of SCID mice. Growth was followed over time by taking caliper mea-
surements at the indicated times.
Protein Expression Analysis
Irs-1 immunoprecipitations were carried out for 3 hr at 4C. Immuno-
precipitates were eluted by boiling samples in 3% SDS for 5 min.
Reporter assays of Jnk activity were done using the PathDetect
c-Jun Trans-reporting System (Stratagene). Cells were transfected
using Lipofectamine 2000 (Invitrogen). Dominant negative MLK3
(pCDNA-MLK3-K144R) was a gift from Dr. Norman Lassam. Dominant
negative RAC1 (pCDNA-Rac1-N17) was a gift from Dr. David Chang.
Constitutively active p110-a (pCG-M-p110*) was a gift from Dr. Anke
Klippel. Transfected cells were lysed and luciferase assays carried
out using the Dual-Luciferase Reporter Assay System (Promega).
Immunohistochemical and Quantum Dot Staining and Analysis
Tissue acquisition for making prostate tissue microarrays was
performed under an approved protocol from the Dana Farber Cancer
Institute Institutional Review Board (IRB99-33). Informed consent for
these studies was received from patients under the terms of IRB 01-
145. Immunohistochemistry (IHC) was performed on 5 mm thick,
formalin-fixed, paraffin-embedded TMA sections using primary
antibodies for PTEN (1:200 dilution, 60 min at room temperature
incubation, Zymed Laboratories, San Francisco, CA), phospho cJUN
Ser 73 (1:50 dilution, overnight 4C incubation, Cell Signaling Technol-
ogy, Danvers, MA), phospho S6 Ser 240/244, (1:100 dilution, overnight
4C incubation, Cell Signaling Technology, Danvers, MA), and pAKT
(Ser 473) (Cell Signaling Technology, Danvers, MA, 1:50 dilution, over-
night 4C incubation). Antigen retrieval was performed for 30 min in
citrate buffer for each antibody, except pAKT where three 5 min cycles
in citrate buffer was used. A BioGenex I 6000 autostainer was used for
all subsequent steps (BioGenex, San Ramon, CA). Secondary anti-
body and DAB disclosure was used for conventional IHC. In the
case of dual quantum dot disclosed immunohistochemistry, Qdot
605 and Qdot 650 (Invitrogen, Carlsbad, CA) were used sequentially
with intervening blocking steps for disclosure of Phospho c-Jun and
PTEN respectively. Duplex Quantum dot signals were deconvoluted
using the Nuance Multispectral Imager (CRI Inc., Cambridge, MA).
TMAs were scored semiquantitatively using an Intensity X Quantity
product: (Intensity: 0 = Negative, 1 = Weak, 2 = Moderate, 3 = Strong;
Quantity: 0 = Negative, 1 = 1%–9% of examined cells positive, 2 =
10%–39% of cells positive, 3 = 40%–69% of cells positive, 4 = 70%–
100% of cells positive). Scores were averaged across replicate cores.
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The Supplemental Data include seven supplemental figures, one sup-
plemental table, and supplemental experimental procedures and can
be found with this article online at http://www.cancercell.org/cgi/
content/full/11/6/555/DC1/.
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